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Thy-1 is a cell surface antigen that is present in large amounts on thymocytcs and 
brain  of rats  and  mice,  and  at  reduced  or  as  yet  undetermined  levels  on  some 
peripheral  lymphoid  cell  populations,  fibroblasts,  epidermal  cells,  and  mammary 
tissue  (1-7).  Two  allclic  forms  of the  molecule,  designated  Thy-l.1  and  Thy-l.2 
(formerly 0-AKR  and  0-CsH)  are found  in  the  mouse  (1).  Only Thy-l.1  has been 
identified thus far in the rat (2). In addition to sharing this alloantigcnic determinant, 
Thy-1 antigens in the mouse and rat share a  xenoantigcnie determinant recognized 
by rabbit antiserum (8, 9). Thy-1 antigen has been purified from rat thymoeytes and 
brain, and has been shown for both tissues to be a  glyeoprotein of mol wt approxi- 
mately 25,000 daltons (10,  11). Thy-1 antigen from mouse thymocytes appears to be 
a glyeoprotein of similar size (11-14). 
Despite these chemical and antigenic similarities, and the broad similarity in tissue 
distribution, there are important differences between the rat and mouse with respect 
to the distribution of Thy-1 antigen among specific lymphohemopoietie cell popula- 
tions.  Thy-1  is  a  general  marker for T  lymphocytes in  the  mouse  (15),  but  is not 
readily detectable on nucleated bone marrow cells (16). Conversely, Thy-1 is present 
on a minority of T  cells in the rat (5), but is readily detectable on as many as 45% of 
nucleated  bone  marrow  cells  (6).  Among  these  cells  are  some  members  of the  B 
lymphocyte and myeloid cell series (17,  18).  Attempts to abrogate mouse thymocyte 
progenitor cell and hemopoictic stem cell activity with anti-Thy-1  alloantisera have 
been unsuccessful  (16,  19-21), although recent reports indicate that a Thy-1-positive 
regulatory cell can enhance the proliferative capacity of mouse hemopoietic stem cells 
(22,  23).  In contrast, anti-Thy-1  treatment of rat bone marrow cells has been found 
to prevent regeneration of granulocytes in a  rat-into-mouse adoptive transfer system 
(21); and Thy-1-positive rat bone marrow cells, isolated on the fluorescence-activated 
cell sorter, have been shown to generate B lymphocytes in irradiated recipients (17). 
These  observations  suggest  that  Thy-1  antigen  in  the  rat  may  be  present  on 
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hemopoietic stem cells and/or on the committed progenitors of the lymphoid, myeloid, 
or erythroid cell series. Using an in vivo spleen colony-forming unit  assay (CFU-S)1 
(24, 25) and highly specific anti-Thy-1 sera, we demonstrate in the present paper that 
Thy-1 antigen is present on pluripotent stem cells in rat hemopoietic tissues at three 
developmental  stages,  viz.  adult  bone  marrow,  neonatal  spleen,  and  fetal  liver. 
Evidence that Thy-1 antigen is present on hemopoietic progenitor cells is the subject 
of a  separate report.  2 
Materials  and  Methods 
Animals.  Fetal, newborn, and young adult (8-10 wk old) male and female Lewis strain rats 
and members of the (Lewis  ×  DA)FI hybrid cross were used as donors of bone marrow and 
lymphoid cells in experiments involving transfer of antibody-treated cells (see below). Time of 
gestation for rat fetuses was determined by vaginal smears (appearance of sperm  --  day 0). 
Breeding stocks of these animals were maintained at  the University of Connecticut  Health 
Center. 4- to 5-wk-old male and female Lewis and  (Lewis  ×  DA)F1 hybrid strain rats were 
used as recipients. The recipients received 800 rads whole body X-irradiation 2 h before they 
were given cells (26). 
Young adult (7-9 wk old) male and female DA, Lewis, and Wistar strain rats were used as 
donors  of bone  marrow  cells  in  experiments  involving transfer  of cells separated  on  the 
fluorescence-activated cell sorter (see below). Breeding stocks of these animals were maintained 
at the Walter and Eliza Hall Institute of Medical Research. 5- to 7-wk-old syngeneic rats were 
used as recipients. The recipients received 750 rads whole body X-irradiation 6 h before they 
were given cells. The irradiation was delivered by a Phillips RT 250 machine operating at 250 
kV under maximum back scatter conditions; half value layer was 0.2 mm copper and midline 
dose rate was 137 rads/min. 
All irradiated rats were maintained on oxytetracyeline, 1.0 mg/ml drinking water. 
4- to 6-wk-old male and female AKR/Jax and AKR/Clum strain mice were obtained from 
The Jackson  Laboratory  (Bar  Harbor,  Maine)  and  Cumberland  Farms  (Clinton,  Tenn.), 
respectively. 
Preparation of Cell Suspensions.  Thymocytes, lymph node cells, spleen cells, bone marrow cells, 
and thoracic duct cells were collected as described previously (26, 27). Blood lymphocytes were 
isolated by the method of Wilson (28).  Lymphocyte-rich fractions of spleen and bone marrow 
cell suspensions were prepared by isopyknic centrifugation on a 6.34%  Ficoll-10.0% Hypaque 
gradient (29). Further enrichment of lymphocyte-like  null cells from bone marrow was effected 
by passage of the lymphocyte-rich fraction through a column of fine glass beads as described 
previously (27).  These cells have been shown  to bear the bone marrow lymphocyte antigen 
(BMLA), but to lack antigens specific for peripheral T  and B cells (27, 30). 
Preparation of Thy-I Antigen from Rat Brain,  The method of Barclay et al. (10) was used with 
some modifications as described elsewhere,  a Thy-1.1 antigenic activity was assayed according 
to the method of Williams et al. (31). 
Antisera.  Heteroantisera to the rat bone marrow lymphocyte antigen (anti-BMLA serum) 
and to rat T  lymphocytes (anti-T-cell serum) were prepared in rabbits according to published 
methods (25, 29). 
Two murine anti-Thy- 1.1 alloantisera were used. The first, raised in AKR/cum mice against 
AKR/J  mouse  thymocytes, was  the  gift of Dr. R.  T.  Acton  (University of Alabama); the 
second, a CBA mouse anti-AKR mouse thymocyte antiserum, was the gift of Dr. A. F. Williams 
(Oxford University). 
1  Abbreviations used in this paper: BMLA, bone marrow lymphocyte antigen; CFU-S, spleen colony-forming 
unit (used synonymously with pluripotent hemopoietic stem cell); FACS, fluorescent-activated cell sorter; 
FITC, fluorescein-conjugated; null, lacking T- and B-cell antigenic markers; RITC, tetramethyl rhodamine 
conjugated; TdT, terminal deoxynucleotidyl transferase. 
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The preparation and  absorption of the rabbit  antiserum to the Thy-1  molecule purified 
from rat brain is described in full elsewhere.  8 Of the anti-Thy-1 antibodies in this serum, 51% 
recognized the  rat-specific xenoantigenic determinant,  41%  recognized the rat-mouse cross- 
reacting xenoantigenic determinant, and approximately 8% recognized the Thy-1.1  alloanti- 
genic  determinant  (assayed as in  [8]).  The  IgG fraction  from  this serum  was  prepared by 
Na2SO4  precipitations, DEAE-Sephadex ion exchange chromatography, and Sephadex G-200 
gel filtration following standard procedures. The  F(ab')2 fragments prepared from  this  (32) 
were conjugated with fluorescein isothiocyanate (Baltimore Biological Laboratories, Cockeys- 
ville, Md.) as described by The and Feltkamp (33). Antibodies with a fluorescein/protein molar 
ratio of between 1.0 and 3.4 were pooled, giving a mean fluorescein/protein ratio of 1.7 for the 
preparation. This rabbit anti-Thy-1 antiserum is referred to as serum number  1 in the text. 
The  F(ab')2 of a  second  rabbit  antiserum  to  rat  brain Thy-1  was  used  for  fluorescence 
microscopy. This serum, the gift of Dr. A. F. Williams (Oxford University), was absorbed for 
1 h at 4°C with 3  ×  l0  s rat spleen cells and 6  ×  l0  s rat lymph node cells per ml of antiserum. 
The  IgG  fraction  was  isolated,  from  which  the  F(ab')2  was  prepared.  Of  its  anti-Thy-1 
antibodies, 45% recognize the rat-specific Thy-1 xenoantigenic determinant, 37% recognize the 
rat-mouse cross-reacting xenoantigenic determinant, and  18% recognize the Thy-1.1 alloanti- 
genic determinant (10). This rabbit anti-Thy-1 antiserum is referred to as serum 2 in the text. 
Rabbit F(ab')2 anti-mouse-IgG purified antibodies, and horse F(ab')~ anti-rabbit IgG purified 
antibodies, were the gift of Dr.  A. F. Williams (Oxford University). Fluorescein-conjugated 
(FITC) goat anti-rabbit IgG and tetramethyl-rhodamine conjugated (RITC) goat anti-mouse 
IgG were obtained from Cappel Laboratories, Inc., Cochranville, Pa.). The latter antiserum 
was  passed  down  a  normal  rat  serum  Sepharose 4B  affinity column  (serum  at  10  mg/ml 
coupled to cyanogen bromide-activated Sepharose 4B)  (Pharmacia Fine Chemicals, N.J.)  to 
remove cross-reacting antibodies to rat immunoglobulins. 
Protein determinations were done by the method of Lowry et al. (34)  using bovine serum 
albumin (Sigma Chemical Co., St. Louis, Mo., Fraction V) as a standard. 
Quantitative Absorptions of Antisera.  Antisera were absorbed with deoxycholate-free purified 
Thy-1  by incubating  (at 4°C)  twofold serial dilutions of the antigen  (in  125  #l of Tyrode's 
buffer with a  starting concentration of 43.5 #g/ml)  with an equal volume of antiserum  (see 
Results for dilutions used). After 30 min  (for immunofluorescence) or 20 h  (for opsonization 
and quantitative radioactive binding assay), the residual titer or antibody binding was assayed 
and  compared  to  that  of the  unabsorbed  serum  to  which  only  buffer  had  been  added. 
Absorption of antiserum with brain and liver homogenate (prepared as [8]) was performed by 
similar 30-min incubations of serial twofold dilutions of the tissue homogenate (initial concen- 
tration of 20 mg protein/ml) with equal volumes of antiserum. After centrifugation (3,000 g, 10 
min) the residual antibody activity was assessed by immunofluorescence. 
Indirect Radioactive Binding Assays.  These were used to give a quantitative measure of antibody 
binding to thymocytes after inhibition of the rabbit IgG anti-rat brain Thy-1 antigen by Thy- 
1 antigen, and have been described (8). 
Immunofluorescence.  Indirect immunofluorescence was performed on frozen sections and on 
cell suspensions as described previously (30, 35). 
Simultaneous immunofluorescence with rabbit and mouse antisera was performed as follows: 
cells in  suspension were  incubated  with  the  first  antiserum  (20  min,  4°C,  10  mM  NAN,), 
washed,  incubated  with  the  second  antiserum  (20  rain,  4°C,  10  mM  NaNa),  washed  and 
incubated  sequentially with  FITC-labeled goat  anti-rabbit IgG  (dilution  1:20)  and  FITC- 
labeled goat anti-mouse IgG  (dilution  1:10).  Routine controls included incubating the two 
antisera in reverse sequence, substituting normal rabbit and/or mouse serum for one or both 
antisera; and reacting the FITC and RITC conjugates against cells coated with antiserum from 
the inappropriate species (i.e. mouse instead of rabbit and vice versa). 
Cocapping experiments using rabbit and mouse antisera were performed as follows. Cells in 
suspension were  incubated  with  the  first antiserum  (20  min,  4°C)  and  developed with  the 
appropriate conjugated antiserum under capping conditions (30 min, 37°C).  The cells were 
washed in cold buffer containing  10 mM NaNs, checked for capping, and smeared on glass 
slides in a cytocentrifuge (Shandon Southern Instruments, Inc., Sewickley, Pa.). The cells were 
then incubated with the second antiserum  (20  rain, 21°C),  washed, and developed with the 
second conjugated antiserum. In a  variation of this procedure, cells were incubated with the 1354  THY-I  ON  RAT  HEMOPOIETIC  STEM  CELLS 
LIGHT SCATTER  FLUORESCENCE INTENSITY 
FtG.  1.  Analysis of Thy-l-positive and Thy-l-negative populations of rat bone marrow cells by 
low angle (0°C) light scatter and fluorescence intensity using the FACS II, (Becton-Dickinson;  laser 
power 0.4 W, wavelength 488 nm; photomultiplier voltage 650; 530 nm 3 cavity band pass filter, 
Ditric Optics;  fluorescence  gain 2;  scatter gain 2). Adult DA strain rat bone marrow cells were 
reacted with FITC rabbit  F(abl)2  anti-rat brain Thy-1  antibodies as described  in Materials and 
Methods  and  Table  IV.  (A)  Scatter  profile of fluorescing  (Thy-I  positive)  cells  (large  dots) 
superimposed on scatter profile of total cells (small dots). Approximately 80% of cells in center peak 
(lymphocytes)  and  26% of cells in right peak (myeloid  and blast cells) fluoresced.  The threshold 
marker for excluding erythrocytes  (left peak) during cell sorting was selected so as to remove fewer 
than 2% fluorescing  (and nonfluorescing)  nucleated cells. (B) Fluorescence profile of nucleated cells. 
The marker defines the threshold above and below which cells were sorted into fluorescing  (Thy-1- 
positive) and nonfluorescing  (Thy-l-negative) populations, respectively. The position of the marker 
coincides with the maximum fluorescence intensity displayed by bone marrow cells after incubation 
with anti-Thy-1  antibodies that had been absorbed with rat thymocytes.  In this figure,  43.6% of 
nucleated cells were Thy-I positive. A detailed description of the cell types represented in the Thy- 
1-positive and Thy-1-negative populations will be presented in a separate report? 
first antiserum under capping conditions (30 min, 37°C) and with the second antiserum under 
noncapping conditions (4°C, 10 mM NAN3) before smearing and developing. Results with both 
procedures were identical. Routine controls were similar to those included in the simultaneous 
immunofluorescence experiments (see above). Additional control experiments are described in 
Results. 
Separation of Thy-l-Positive and Thy-l-Negative Bone Marrow Cells.  A Becton Dickinson fluores- 
cence-activated  cell sorter  (FACS  II)  (36)  was  used  to  separate  Thy-l-positive  and  Thy-1- 
negative cells from rat bone marrow. For these experiments 200  ×  l0  s nucleated bone marrow 
cells from young adult  DA, Lewis, and Wistar strain  rats were incubated  for 20 min at 4°C 
with 0.12-1.9 #g fluorescein-conjugated rabbit  F(ab')2 anti-rat brain Thy-1  antibodies in 0.25 
ml Eisen's balanced salt solution. The cells were washed three times in buffer and diluted to a 
concentration of 5  X  10  s ceils/ml for sorting on the FACS. Erythrocytes were gated electroni- 
cally  according  to  their  distribution  profile under  0°C  light  scatter,  using  a  threshold  that 
excluded fewer than  2% of nucleated bone marrow cells (Fig.  1 A). The nucleated cells were 
sorted into Thy- 1-positive and Thy- 1-negative populations according to intensity of fluorescence 
as described under Results and Fig. 1 B. 
Antibody Treatment of Donor Cells.  Sensitization of donor cells with antibody was conducted 
as described previously (26).  Briefly, 1 ×  106-1  ×  10  s donor cells were incubated for 20 min at 
4°C  with  0.05  ml  of appropriately  diluted  rabbit  or  mouse  anti-Thy-l.1  serum  or  normal 
serum. The treated cells were washed twice in cold Tyrode's solution, checked for viability by 
trypan  blue  dye  exclusion,  and  diluted  for  injection.  The  presence  of  mouse  or  rabbit 
immunoglobulin on the treated rat cell was verified by indirect immunofluorescence. 
Spleen Weight and CFU-S Assays.  1 ×  106-1  ×  10  s antibody-treated adult rat bone marrow, 
neonatal spleen, or fetal liver cells in  1.0 ml Tyrode's solution were injected i.v. into syngeneic 
rats  that  had received 800 rads whole body X-irradiation  2 h  previously. 0.4  ×  106-1  ×  106 
FACS separated adult rat bone marrow cells in  1.0-2.0 ml Eisen's balanced salt solution were 
injected  i.v.  into  syngeneic  rats  that  had  received  750  rads  whole  body  X-irradiation  6  h 
previously.  The recipients were sacrificed  12  days after injection. The spleens were weighed, 
fixed, and examined for macroscopically visible colonies (26). Selected spleens were embedded 
in paraffin, sectioned, and stained with hematoxylin and eosin for microscopic examination of 
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Complement-Mediated Cytotoxicity.  2.5  ×  10  ~ nucleated rat bone marrow,  thymus, spleen, or 
lymph  node  cells  in  25  #I  Dulbeeco's  phosphate-buffered  saline  plus  10  mM  NaNa  were 
incubated  (30 min, 4°C:)  with  50 #1 appropriately diluted antiserum or normal serum.  Cells 
were then washed once and incubated for 60 min at  37°C  with 0.1  ml complement  (normal 
Lewis rat serum). Viability counts were performed by trypan blue dye exclusion. The specificity 
and  extent  of  the  killing,  as  compared  to  the  normal  serum  control,  was  confirmed  by 
examination of the surviving cells by immunofluorescenee (27). 
Results 
Distribution of Thy-l-Positive  Cells in Rat Lymphohemopoietic Tissues.  The distribution 
of putative Thy-l-positive cells in  the lymphohemopoietic tissues of normal rats  is 
shown in Table I. The highest percentages of positive cells are found in bone marrow, 
thymus and spleen;  the lowest percentages are in lymph node, blood, and thoracic 
duct lymph. The same proportions of positive cells were obtained in indirect immu- 
no  fluorescence  assays  and  in  complement-mediated  cytotoxicity assays  using  two 
different lots of rabbit anti-rat brain Thy-1 serum (Materials and Methods). 
In frozen sections of rat thymus the rabbit F(ab')2 anti-Thy-1 antibodies (serum 2) 
labeled cortical thymocytes much more intensely that it did medullary thymocytes. 
Consistent  with  this  was  the  finding that  strongly Thy-l-positive  thymocytes are 
sensitive to cortisone. The 53% reduction produced by this steroid in the proportion 
of Thy-l-positive thymoeytes (Table I) represents an absolute decrease of 92% in the 
total number of Thy-1-positive cells. Thy-1-positive cells in bone marrow and spleen 
are similarly sensitive to cortisone (Table I). 
Inhibition of the Binding of Rabbit IgG Anti-Rat Brain Thy-I to Thymocytes.  To assess the 
specificity of the reaction of the rabbit anti-rat brain Thy-1 antiserum, the binding of 
a  constant amount  (1.5 #g)  of the IgG fraction of this antiserum  (serum  1)  to rat 
thymocytes was inhibited by a  prior incubation of the antibody with serial twofold 
TABLE  I 
Distribution of Thy-l-Positive Cells in Rat Lymphohemopoietic Tissues 
Ti~ue~ 
Per cent Thy- l-positive cells (mean ± 
SE)* 
Untreated  Cortisone-treated§ 
Bone marrow  21.0  ±  1.7  5.2  ±  0.8 
Thymus  92.0  ±  1.2  43.4 ±  2.1 
Spleen  19.3 4- 2,0  4.1  4- 0.4 
Lymph node  3.6 ±  0,5  5.5  ±  0.6 
Blood  7.2 ±  1.9  NDI] 
Thoracic duct lymph  8.1  ±  0.4  ND 
Neonatal spleen (3 day)  36.6  3= 3.2  ND 
Fetal liver (16 day)  1.2 3= 0.3  ND 
* Determined by indirect immunofiuorescence using rabbit F(ab~)2 anti-rat 
brain Thy-1 at a  final concentration of 0.08 mg protein/ml; normal rabbit 
F(ab')2 at the same concentration was used as a control. Values given are the 
net percent of nucleated cells that fluoresced.  Note for fetal liver this includes 
erythrocytes. Mean of three to five experiments. 
:]: Cells from (Lewis  ×  DA)F1 hybrid rats, 8- to 10-wk-old for the adult tissues. 
§ Donors injected i.m. 3 days previously with 50 mg cortisone acetate per 100 
g body weight. 
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FIG.  2.  Inhibition by pure Thy- 1 antigen of rabbit IgG anti-rat brain Thy- 1 serum. Duplicate 90- 
/.d aliquots of the antigen, in doubling dilutions from 1.04 to 0.1 p,g were incubated at 40C for 20 h 
with  1.5 p,g of the IgG fraction of the rabbit anti-rat brain Thy- 1 serum (giving a  final antibody 
dilution equivalent  to  1:1,600  of the serum).  Rat  thymocytes (30  ~1  at  2  X  10S/ml)  were then 
added, and the antibody binding to these measured by the indirect radioactive binding assay  7 (8). 
The binding of unabsorbed serum (38,000  cpm) and of serum absorbed with an excess (4  ×  10 ) of 
rat thymocytes (2,450  cpm) was also measured. The specific binding of unabsorbed serum (35,550 
cpm) was equivalent to 0.78 pmol of rabbit IgG bound (calculated as in references 8 and 47). The 
specific binding of the antiserum absorbed with Thy- l  antigen was then expressed as a percent of 
the maximum specific binding, and this was subtracted from  100% to give the percent inhibition 
obtained (ordinate), The moles of Thy-1  present at each point (mol wt 24,000 dahons)  (10)  were 
divided by the moles of antibody present (0.78 pmol) to give the molar ratio shown on the abscissa. 
dilutions of pure Thy-1  antigen.  More than 90% of the  inhibition occurred in  the 
range of 2-10 ng of Thy-1 antigen;  and  25 ng reduced binding to the background 
level. It can be seen in Fig. 2 that the inhibition occurs steeply around the equimolar 
ratio of antigen to antibody. 
Two probable sources of error in the calculation of the amount of Thy-1 antigen 
should be noted.  This was  estimated by the  Lowry et  al.  method  (34)  for protein 
determination, using bovine serum albumin as the standard.  The latter protein has 
1.68 the tyrosine content of Thy-1  (37, 38)  (the major amino acid measured in this 
protein determination); moreover bovine serum albumin is not a glycoprotein, whereas 
29% by weight of rat brain Thy- 1 is carbohydrate whose mass is obviously not assayed 
in the protein determination. Both these sources of error would lead to an underesti- 
mate of the true amount of Thy-1, by as much as 2.4-fold in all, so that the antigen: 
antibody ratio in Fig. 2 almost certainly underestimates the true ratio, possibly by as 
much as this factor. 
Effect of Rabbit Anti-Rat Brain  Thy-1  Antiserum on CFU-S in Bone Marrow.  Results in 
Table II show that the rabbit anti-Thy-1 antiserum (serum 1) in dilutions from 1:I00 
to 1:5,000, was able to completely abrogate the spleen CFU-S activity of adoptively 
transferred  adult  rat  bone  marrow  cells.  50%  inhibition  of CFU-S  activity  was 
observed at a  1:10,000 dilution of the antiserum. A similar degree of inhibition by the 
antiserum of the ability of bone marrow ceils to increase spleen weight in irradiated 
recipients was observed. Prior absorption of the antiserum with pure rat brain Thy-1 
antigen removed the ability of the antiserum to inhibit CFU-S activity and to prevent IRVING GOLDSCHNEIDER,  LANCE  K.  GORDON,  AND ROGER J.  MORRIS 
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Effect of Anti-Thy-1 Serum on CFU-S in Rat Bone Marrow 
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Treatment of bone marrow cells* 
Antiserum (dilution)§ 
Parameters measured (mean ±  SE):I: 
Absorbed with 
Thy-1 antigen ~  Spleen colonies  Spleen weight 
Normal  rab- 
bit serum 
(1:100)  --  13.9  ±  0.8  127 ±  10 
(1:100)  2.00  14.6 ±  0.9  138 ±  13 
Anti-Thy-I  (1:100)  --  1.6 ±  0.3  98 ±  9 
(1:500)  --  1.1:1:0.3  95 ±  8 
(1:500)  2.00  13.8 ±  0.5  140 ±  11 
(1:500)  0.67  12.8 ±  1.0  130 ±  12 
(1:500)  0.33  12.4 ±  0.3  145 ±  10 
(1:2,500)  --  1.6 ±  0.4  88 ±  7 
(1:5,000)  --  0.7 ±  0.3  98:1:16 
(1:10,000)  --  6.3  3=  0.9  154 :t: 42 
(1:20,000)  --  13.0 ±  1.5  139 ±  24 
* See Materials and Methods for details. 
1 X  10  ° nucleated  bone marrow cells from 8- to  10-wk-old (Lewis X  DA)F1 strain  rats 
were injected i.v. into irradiated (800 rads) 4- to 5-wk-old syngeneic recipients. Each entry 
represents the mean of six experiments (total 12-24 surviving animals per entry). The data 
were collected  12 days after injection of donor cells. Values for irradiated rats not given 
bone marrow cells were: spleen colonies, 2.0:1: 0.5; spleen weight, 54 ±  7. 
§ Rabbit anti-rat brain Thy-1 antiserum  (serum 1). 
[I The amount of purified Thy- 1.1 antigen shown, in  125/.d, was added to 125 #1 of diluted 
serum 16 h before treatment of bone marrow cells. 
spleen weight gain. Allowing for the 1.8-fold larger vol and 4.9-fold higher concentra- 
tion of the antiserum used in this assay, 0.33 #g Thy-1  used here is equivalent to 37 
ng used in Fig. 2, or an antigen: antibody molar ratio of 1.9. 
Further evidence of the specificity of the reaction against stem cells was obtained 
using  two  murine  anti-Thy-l.1  alloantisera. AKR/Cum  anti-AKR/Jax  thymoeyte 
antiserum (dilution 1:20) was found to completely inhibit CFU-S activity in adult rat 
bone  marrow.  This  inhibition was  prevented  by prior absorption  of the  antiserum 
with  purified  rat  brain  Thy-I  antigen,  or  with  AKR/Jax  (Thy-l.1  type)  but  not 
AKR/Cum  (Thy-l.2  type)  brain  homogenates.  CBA  mouse  anti-AKR  mouse  thy- 
mocyte serum  (dilution 1:20) was similarly effective in inhibiting the CFU-S activity 
of adult rat bone marrow. 
Effect of Anti-Thy-1 Antiserum on CFU-S in Neonatal Spleen  and Fetal Liver.  In Table 
IIIa the  increase in  spleen weight  and  number  of spleen colonies after injection of 
increasing numbers  of spleen cells from  3-day-old rats  is shown.  Incubation  of the 
highest  number  of cells used  (10 T  )  with  increasing dilutions of rabbit anti-rat brain 
Thy-1  serum  inhibited  the  CFU-S  activity as  assessed  by  both  parameters  (Table 
IIIb). An approximately fourfold higher concentration of antiserum than that required 
for the adult bone marrow cells was needed for comparable inhibition, reflecting the 
larger cell inoculum used and higher proportion ofThy-l-positive cells in the neonatal 
spleen. 
The  mean  spleen  weights  obtained  with  increasing numbers  of neonatal  spleen 
cells, and with  107 spleen cells treated with various dilutions of anti-Thy-1 antiserum, 1358  THY-I  ON  RAT  HEMOPOIETIC  STEM  CELLS 
are plotted in Fig. 3. It can be seen that not only is the relationship of spleen weight 
to numbers of injected cells approximately linear, so also  is the abrogation of this 
activity by anti-Thy-l-serum. Moreover, the dose-response curves are virtually coin- 
cidental, 
The  rabbit  anti-rat  brain  serum  was  similarly  effective in  eliminating  CFU-S 
activity in  16 day fetal rat liver. 
CFU-S Activity  in  Thy-l-Positive  and  Thy-l-Negative  Populations of Bone Marrow  Cells 
Separated by the Fluorescence-Activated Cell Sorter (FACS).  Bone marrow cells from young 
adult  DA  strain  rats  were  incubated  in  vitro  with  fluorescein-conjugated  rabbit 
F(abl)~ anti-rat brain Thy- 1 antibodies (serum 1). Thy- 1-positive and Thy- 1-negative 
populations of nucleated cells were separated on the FACS. Almost complete sepa- 
ration (>98% purity) of these populations was possible because of the sharp bimodality 
of fluorescence intensity (Fig.  1). 
Between 38.5 and 49.0% (mean 44.9%)  of nucleated bone marrow cells were Thy-1 
positive by FACS  analysis.  4 The percentage of Thy-l-positive cells was constant at 
antibody concentrations of 0.5-7.5/zg protein/ml/8  X  108 nucleated cells.  Antibody 
activity was reduced to background levels by absorption with rat thymoeytes. 
Results  in  Table  IV  show  that  all  CFU-S  in  DA  rat  bone  marrow  are  Thy-1 
positive. In a series of four experiments using FACS separated cells, 1 X  10  n Thy-1- 
positive bone  marrow  cells  produced  a  mean  of 59.6  hemopoietic colonies in  the 
spleens of irradiated recipients; whereas  1  ×  106 antibody-treated but unseparated 
bone marrow cells, containing a mean of 40.1% Thy-1-positive cells, produced a mean 
of 25.3 spleen colonies. This represents a  2.6-fold enrichment in CFU-S activity (or 
100% recovery) when the data are corrected for a mean of 3.3 endogenous colonies. In 
contrast,  1  ×  108  FACS  separated  Thy-l-negative cells  failed  to  produce  spleen 
colonies above background levels. 
Complete recovery of CFU-S  activity in the Thy-l-positive cell fraction was also 
obtained with FACS separated Lewis strain (two experiments) and Wistar strain (one 
experiment) rat bone marrow cells. 
In  another  series  of experiments, Thy-l-positive cells were sorted on  the  FACS 
according to relative fluorescence intensity. More than 90% of CFU-S  activity was 
recovered within the upper 25th percentile of fluorescent cells. 
In none of the above experiments did the F(abl)2 anti-Thy-I antibodies, used at a 
concentration of 1.9/~g/ml/8  X  l0  s nucleated bone marrow cells, alter the ability of 
CFU-S  to  migrate  to  spleen  and  to  form  hemopoietic  colonies  there  (compare 
antibody-treated  to  untreated  bone  marrow  cell  controls  in  Table  IV).  However, 
antibody concentration of 7.5  ~tg/ml/8  X  108 cells caused  an  approximately 50% 
decrease in the  number of spleen colonies, due at  least  in  part  to agglutination  of 
Thy- 1-positive cells. 
Relation of the Thy-1 Antigen to the Rat BMLA.  In the rat (5, 6, and this paper) and 
the mouse (data not shown) the same proportions of thymus, spleen, lymph node, and 
bone marrow cells that react with anti-Thy-1 serum also react with antiserum to the 
4 Values  for  Thy-l-positive  cells  similar  to  those  determined  by  FACS  analysis  were  obtained  by 
fluorescence microscopy. These values are significantly greater than those recorded in Table I  (45 versus 
21% Thy-l-positive bone marrow cells).  In as much as the reagents and sensitivities of the immunofluores- 
cence assay systems were identical,  the disparity in results probably reflects  differences between the two 
stocks of DA strain rats that were used (Materials and Methods). Such intrastrain differences in percentage 
of Thy-l-positive rat bone marrow cells have been reported by Hunt et al.  (17). IRVING  GOLDSCHNEIDER,  LANCE  K.  GORDON,  AND  ROGER J.  MORRIS 
TABLE  III 
Abrogation of CFU-S Activity in Rat 3 Day Spleen by Rabbit Anti-Rat Brain Thy-I 
Antiserum* 
1359 
A.  Spleen weight gain and colony formation induced by 3 day spleen cells: dose- 
response relationship 
Cell dose~  Spleen weight ±  SE  Spleen colonies  ± 
SE 
mg 
None  74.1 ±  4.5  2.1  ±  0.5 
5 X  10  n  74.2 "4" 8.9  7.4 ±  1.5 
1 ×  106  81.8 ±  9.9  13.4 ±  3.1 
5  X  l0  n  120.6:1:15.1  38.0 ±  8.1 
1 X  107  149.0 ±  19.6  TNTC§ 
B.  The abrogation of CFU-S activity in 1 ×  1073 day rat spleen cells by treatment 
with rabbit anti-rat brain Thy-I serum 
Dilution of anti-Thy-I serum  Spleen weight ±  SE  Spleen colonies  + 
SE 
mg 
1:500  70.5 ±  5.2  3.6 ±  2.5 
1:1,250  85.9 ±  16.2  4.1  ±  1.0 
1:2,500  104.1  ±  10.8  6.6 ±  1.1 
1:5,000  119.6 ±  8.8  34.9 ±  5.9 
1:10,000  142.0 ±  32.8  TNTC 
Normal rabbit serum 
1:500  169.8 ±  23.0  TNTC 
* Data represents the mean values for survivors from three to four experiments, 3-12 
animals per point. 
Cell numbers are total cells injected, including erythrocytes. 
§ TNTC, too numerous to count. 
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FIG.  3.  Spleen weight response to increasing numbers of 3 day donor spleen ceils and to increasing 
dilutions of rabbit  anti-rat  brain  Thy-1  serum.  (©)  is  the  mean  spleen  weight  in  response  to 
increasing cell dose (bottom abscissa);  (D) is the mean spleen weight in response to 107 spleen cells 
treated with increasing dilutions of rabbit anti-rat brain Thy-I serum.  Data from Table III. 
bone marrow  lymphocyte antigen (anti-BMLA)  (27).  Both antisera have been shown 
to abrogate CFU-S  activity in adult rat bone marrow  (26, and this paper). 
That  the  Thy-1  and  BMLA  antigenic  determinants  are  present  on  the  same 1360  THY-1  ON  RAT  HEMOPOIETIC  STEM  CELLS 
TASLE  IV 
CFU-S Activity m Thy-l-Positive  and Thy-l-Negative  Populatwns of DA Rat Bone Marrow Cells 
Separated by the FACS 
Treatment of bone marrow cells 
Fraction  Spleen colonies 
Incubated with  Separated by  Per cent Thy-1  (mean :1: SE) I[ 
anti-Thy- 1  *  FACS:~  positive§ 
Buffer control  --  --  --  3.3  +  0.6 
Untreated, unseparated  No  No  --  28.5  ±  2.3 
Treated, unseparated  Yes  No  40.1  25.3  ±  2.2 
Thy-1 positive  Yes  Yes  >98  59.6  ±  5.8 
Thy-1 negative  Yes  Yes  <2  3.3  ±  0.7 
* FITC  rabbit  F(ab')~ anti-rat  brain  Thy-1  antibodies were  used  at  a  final  concentration of  1.9 ~g 
protein/ml/8 ×  108 nucleated bone marrow cells. 
:1: See Fig.  1 for conditions of cell separation. 
§ Percent of nucleated cells. 
II Irradiated (750  rads)  syngeneic recipients were injected i.v. with buffer or with 0.4  ×  108-1.0  ×  10  n 
nucleated bone marrow cells. Spleen colonies were counted on day  12. Data represents the mean values 
for survivors from four experiments, 12-16 animals per point, normalized to 1 ×  106 injected cells. 
TABLE  V 
Cocapping of BMLA and Thy-l.1 Antigens on Rat Thymocytes 
Experimental protocol* 
First antiserum +  developing anti-  Second antiserum +  developing  Immunofluorescence patternll 
serum  antiserum 
(Capping conditions):~ 
NRS  +  FI-GAR-Ig 
NRS  +  FI-GAR-Ig 
R-anti-BMLA +  FI-GAR-Ig 
R-anti-BMLA +  FI-GAR-Ig 
(Noncapping conditions)§ 
NMS  +  Rh-GAM-Ig 
M-anti-Thy-l.1  +  Rh-GAM-Ig 
NMS  +  Rh-GAM-Ig 
M-anti-Thy-l.1 +  Rh-GAM-Ig 
No staining; no capping 
Rh staining; no capping 
FI capping only 
FI and Rh cocapping 
NMS  +  Rh-GAM-Ig 
NMS  +  Rh-GAM-Ig 
M-anti-Thy-l.1  +  Rh-GAM-Ig 
M-anti-Thy-l.1  +  Rh-GAM-Ig 
NRS  +  FI-GAR-Ig 
R-anti-BMLA +  FI-GAR-Ig 
NRS  +  F1-GAR-Ig 
R-anti BMLA +  FI-GAR-Ig 
No staining; no capping 
Fl staining; no capping 
Rh capping only 
F1 and Rh cocapping 
R-anti-T +  F1-GAR-Ig 
M-anti-Thy-l.1  +  Rh-GAM-Ig 
M-anti-Thy-l,1  +  Rh-GAM-Ig 
R-anti-T +  F1-GAR-Ig 
Rh staining; FI capping 
FI staining; Rh capping 
* See Materials and Methods for details. NRS, normal rabbit serum; NMS, normal mouse serum; R-anti- 
BMLA, rabbit antiserum to rat bone marrow lymphocyte antigen; M-anti-Thy-l.1, AKR/cum mouse 
anti-AKR/J mouse thymocyte serum; R-anti-T, rabbit antiserum to rat T  cells; F1-GAR-Ig,  FITC goat 
IgG anti-rabbit IgG; Rh-GAM-Ig, RITC goat IgG anti-mouse IgG. 
:~ 37°C, 30 min. 
§ 4°C,  10 mM NAN3, 20 rain. 
II FI, fluorescein (green)  fluorescence;  Rh, rhodamine (red)  fluorescence;  staining, uniform circumferential 
pattern of surface fluorescence;  capping, broken polar pattern of surface fluorescence;  cocapping, complete 
superimposition of FI and Rh caps on cell surface. 
molecule was demonstrated  by double immunofluorescence  in which the appropriate 
fluorescein-  and  rhodamine-conjugated  antisera  were  used  simultaneously  to  detect 
both  antigens  (Materials  and  Methods).  All  rat  thymocytes  and  bone  marrow  cells 
which  had  Thy-l.1  antigen  also  had  BMLA,  and  vice  versa.  Moreover,  capping  of 
either of these antigens with its appropriate  antiserum  caused the capping  of the other 
antigen.  Results of an experiment  with thymocytes  are presented in Table  V; similar IRVING GOLDSCHNEIDER, LANCE  K.  GORDON,  AND ROGER J.  MORRIS  1361 
results were obtained with bone marrow cells. 
As a  control for the specificity of the cocapping phenomenon, rabbit  anti-T-ceU 
serum (absorbed with rat bone marrow cells) was substituted for anti-BMLA in the 
above system. Although the anti-T-cell serum caused complete capping of the relevant 
T-cell  antigen(s)  on  thymocytes, cocapping  with  Thy-l.1  antigen  did  not  occur. 
Conversely, capping with anti-Thy-1.1 serum did not cause cocapping of antigen(s) 
detected by the anti-T-cell serum. 
The  conclusion that  Thy-1  and  BMLA are  on  the  same  molecule was  further 
substantiated by the following observations. Binding of anti-BMLA serum to rat bone 
marrow, thymus, and spleen cells was completely prevented by absorption with small 
quantities  of rat  or  AKR/J  mouse  brain  homogenate.  Anti-BMLA  serum  was 
neutralized by purified Thy-1 antigen used at the minimum concentration required 
to neutralize rabbit anti-Thy-1 serum of equal titer. 
Discussion 
We have used three experimental approaches to demonstrate that Thy-1 antigen is 
present on pluripotent stem cells in rat hemopoietic tissues:  (a)  depletion of Thy-1- 
positive cells by treatment with anti-Thy-1 antibodies; (b) isolation of Thy-l-positive 
and Thy-1-negative cells by the FACS; and (c) demonstration that Thy-1 and BMLA 
antigens are present on the same molecule. The CFU-S assay was used to specifically 
identify and quantify pluripotent stem cells. This assay detects clones of erythrocytic 
and myelocytic cells that are formed by individual stem cells; the number of colonies 
formed  being  a  linear  function  of the  number  of hem0poietic  cells  injected.  A 
derivative assay, the spleen weight assay, was used as a general measure of hemopoietic 
regenerative capacity. 
Rabbit antiserum to purified rat brain Thy-1 molecule was used in the first set of 
experiments. The CFU-S activity of adult bone marrow was completely abrogated by 
dilutions of antiserum up to 1:5,000;  and 50% inhibition was observed at 1:10,000. At 
such dilutions it seems unlikely that any antibodies except those to the Thy-1 antigen 
could be responsible. Moreover, this inhibition was completely neutralized by purified 
rat  brain Thy-1 antigen, used here at antigen: antibody molar ratios of as little as 
1.9:1.  Other  evidence of the  specificity of the  anti-Thy-1  serum  was provided  by 
antibody binding studies  using thymocytes as  target  cells.  Inhibition of antibody 
binding by purified rat brain Thy-1 antigen occurred steeply around the equimolar 
antigen:  antibody range.  Under  these conditions, any minor contaminants of the 
purified antigen which might have escaped detection on the sodium dodecyl sulfate 
polyacrylamide gels could not have inhibited the action of the anti-Thy-1 serum. 
The conclusion that the effect of the rabbit antiserum on rat CFU-S activity Was 
specifically mediated by anti-Thy- 1 antibodies was further substantiated by using two 
murine  anti-Thy-1  alloantisera.  The  first  of these,  the  AKR/Cum  anti-AKR/J 
thymocyte serum, is raised between two mouse strains for which Thy-1  is the only 
known cell surface antigenic difference (39). That the abrogation of CFU-S activity 
was due to anti-Thy-1.1 antibodies in this serum was demonstrated by the neutrali- 
zation of this effect by the rat brain Thy-1 antigen, and by absorption of the antiserum 
with the brain homogenate from the Thy-1.1 but not the Thy-l.2 type mouse strain. 
The second anti-serum, CBA anti-AKR thymocyte serum, which has been shown to 
only recognize the Thy- 1.1 antigen on rat thymocytes by absorption with tissues from 1362  THY-1 ON RAT HEMOPOIETIC STEM CELLS 
Thy-1  congenic mouse strains  (31), was  equally effective in abrogating the CFU-S 
activity of adult rat bone marrow cells. 
Additional evidence for the presence of Thy-1 antigen on hemopoietic stem cells is 
the finding that rabbit antiserum raised against a population of lymphocyte-like null 
cells from rat bone marrow (anti-rat bone marrow lymphocyte antigen serum; anti- 
BMLA serum)  (27)  reacts with Thy-1 antigen. Anti-BMLA serum has already been 
shown to eliminate CFU-S activity in adult rat bone marrow (26). Here we show that 
BMLA and Thy-1.1 occur on the same cells in rat bone marrow, and that antiserum 
to either antigen causes a redistribution (capping) of both antigens to the same area 
of the cell. Such cocapping has only been observed for antigens which are physically 
linked, such as/0-2 microglobulin and HLA on human lymphocytes (40).  Since the 
purified  rat  brain  Thy-1  antigen  fully inhibits  the  binding  of anti-BMLA  to  rat 
lymphocytes, this physical linkage of the two antigens must be by virtue of their being 
determinants on the same Thy-1 molecule. 
It is clear from the preceding experiments that anti-Thy-1 sera, raised by diverse 
methods, can completely abrogate CFU-S activity in suspensions of adult  rat bone 
marrow  cells;  and  that  this  effect can  be prevented by neutralization with  Thy-1 
antigen.  It  is  not  clear, however, that  the suppression of CFU-S  activity is due to 
reaction of anti-Thy-1 antibodies directly with CFU-S. Alternatively, the effect may 
be at the level of Thy-l-positive cells which regulate the proliferation of CFU-S, as 
demonstrated in the mouse (22, 23). Assuming that  anti-Thy-1 antibodies do react 
with  CFU-S,  it  is  possible  that  they  do  so  nonspecifically  by  binding  to  Fc  or 
complement receptors. 
Results of experiments using the FACS show unequivocally that Thy-1 antigen is 
present on CFU-S. Thus, all CFU-S activity originally present in unseparated bone 
marrow cell suspensions was recovered in the Thy-1-positive cell population; whereas 
no CFU-S activity was present in the Thy-l-negative population. The use of F(abl)2 
fragments of anti-Thy-1 antibodies precluded nonspecific reactions with Fc or com- 
plement receptors. It could be argued of course that hemopoietic stem cells have only 
trace  amounts  of Thy-1  antigen  on  their surface,  and  that  one  is  dealing with  a 
threshold phenomenon in a highly sensitive assay system. This is not the ease. Results 
of experiments in which Thy-l-positive bone marrow cells were separated according 
to  relative  fluorescence intensity  (and  hence  relative  amounts  of Thy-1  antigen) 
indicate  that  CFU-S  are  among  the  most  highly  fluorescent subsets  of cells.  The 
results also indicate that if accessory cells exist in rat bone marrow, they too must be 
strongly positive for Thy-1 antigen. 
Given that Thy-1 antigen is present on hemopoietic stem cells in adult  rat bone 
marrow, it was of interest to determine if this was also true for stem cells in neonatal 
spleen  and  fetal  liver.  Stem  cells  in  the  latter  tissues  have  been  shown  to  differ 
significantly from stem cells in adult bone marrow with respect to physical character- 
istics and proliferative capacities  (41).  The relationship between these two types of 
stem cells is not clear, but there is evidence to suggest that the former can give rise to 
the latter. The present experiments show that embryonic-type stern cells, like adult- 
type stem cells, are Thy-1 positive. CFU-S activity in suspensions of 16 day fetal liver 
cells was completely abrogated by treatment with rabbit anti-rat brain Thy-1 anti- 
serum.  At  this stage of development, the majority of Thy-1  positive cells have the 
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Anti-Thy-1 serum also abrogated stem cell activity in suspensions of 3 day neonatal 
spleen  cells as assayed by spleen  colony formation and spleen  weight  gain.  At  less 
than saturating antibody dilutions  (1:1,250 to  1:10,000)  spleen weight gain after the 
injection  of 1  ×  107 treated cells was directly proportional  to the  dilution  of anti- 
Thy-1  serum  used.  The  slope of the  resultant  curve  (Fig.  3)  was  identical  to  that 
formed by the injection of 5  ×  105-1  ×  10  7 untreated cells. The correspondence of 
these two dose-response curves strongly suggests that the anti-Thy-1 antibodies acted 
directly on the stem cells. 
The proportions of rat  lymphohemopoietic cells that were labeled by anti-Thy-1 
sera  in  the  present  study  are  in  good  agreement  with  reported  values  (5,  6),  in 
particular  the high percentage of Thy-l-positive cells in bone marrow (between  21 
and 45%  of nucleated  cells),  and  the  low percentages in  lymph node  and  thoracic 
duet  lymph  (less  than  10%) have been confirmed.  In addition,  most Thy-l-positive 
cells  in  rat  bone  marrow,  spleen  and  thymus  cortex  were  found  to  be  cortisone 
sensitive. Assuming a  frequency of 0.7  for pluripotent stem cells (42)  and of 20% for 
Thy-l-positive cells, it is evident that the stem cells comprise a  maximum of 3.5% of 
Thy-l-positive  cells  in  rat  bone  marrow.  Moreover,  they  appear  to  belong  to  a 
cortisone resistant subset of Thy-l-positive cells. 2 
The  identity  of the  remainder  of the  Thy-l-positive bone  marrow  cells  is  only 
partially known.  Using an  in  vitro colony-forming unit  assay (43),  we have shown 
that progenitors of myeloid cells and of some B cells are Thy-1 positive.  20ntogenetic 
studies of Ig-positive cells also support the notion that immature members of the B- 
cell  series  are  Thy-1  positive  (18).  Moreover,  Thy-l-positive  bone  marrow  cells, 
isolated  by  the  FACS,  have been  shown  to  generate  B  lymphocytes in  irradiated 
recipients (17). However, it is not possible to tell whether this was due to the transfer 
of pluripotent stem cells and/or B cell progenitors. 
It also seems likely that Thy-1 antigen is present on thymocyte progenitors in the 
rat, but an independent  marker for such ceils has yet to be identified in this species. 
One  promising  molecule  in  this  respect  is  the  enzyme  terminal  deoxynucleotidyl 
transferase (TdT), which in the rat is normally restricted to cortical thymocytes and 
to a small subset (1-4%) of cells in the bone marrow and prepubertal spleen (44-46). 5 
Several  lines  of evidence  suggest  that  at  least  some  of these  could  be  thymocyte 
progenitors  (46-48). 6 Recently we have isolated highly enriched  (greater than 90%) 
populations of viable TdT-positive cells from rat bone marrow] Experiments are in 
progress to determine the developmental potential of such cells, all of which have the 
Thy-1 phenotype. 
Summary 
Three approaches were used to demonstrate the presence of Thy-1 antigen on the 
surface of pluripotent  hemopoietic stem cells in the rat. In the first, stem cells from 
b K. E. Gregoire et al. Ontogeny of terminal deoxynucleotidyl transferase positive cells in the rat. 
Manuscript in preparation. 
s I. Goldschneider, et al. Induction of terminal deoxynucleotidyl  transferase and Ly antigens in mouse 
bone marrow and spleen cells  with thymosin: demonstration  by immunofluorescence.  Manuscript submitted 
for publication. 
'1. Goldschneider, et al. Isolation of terminal deoxynucleotidyl transferase positive rat bone marrow 
cells on the fluorescence-activated  cell sorer. Manuscript submitted for publication. 1364  THY-1  ON RAT HEMOPOIETIC STEM  CELLS 
fetal  liver,  neonatal  spleen,  and  adult  bone  marrow  were  prevented  from  forming 
hemopoietic  colonies  in  the  spleens  of irradiated  recipients  spleen  (colony-forming 
unit  assay)  by incubation  with  antibodies  to Thy-1  antigen.  Highly specific rabbit 
heteroantiserum  to purified rat brain Thy-1 antigen and mouse alloantisera  to Thy- 
1.1-positive  thymocytes were  equally  effective.  This  inhibition  was  neutralized  by 
purified Thy-1 antigen. 
In a  second series of experiments,  Thy-1-positive and Thy-l-negative populations 
of nucleated bone marrow cells were separated by the FACS. All of the hemopoietic 
stem cell activity was recovered in the Thy-1-positive population. The stem cells were 
among the most strongly positive for Thy- 1 antigen, being in the upper 25th percentile 
for relative fluorescence intensity. 
The  relationships  of Thy-1  antigen  to the  rat  bone marrow  lymphocyte antigen 
(BMLA) was shown in a third series of experiments.  Rabbit anti-BMLA serum, which 
is  raised  against  a  null  population  of lymphocyte-like bone marrow cells,  has  been 
shown to have anti-stem  cell activity.  Here we demonstrate by double immunofluo- 
rescence,  cocapping, and  differential  absorption  studies  that  Thy-1  and  BMLA are 
parts of the same molecule. 
We wish to acknowledge the excellent technical assistance of Mrs. Frances Tausche and Mr. 
Roderick Mitchell. We are also grateful to Dr. Frank Battye for his expert advice and assistance 
in the operation of the fluorescence-activated cell  sorter;  and to Dr.  Donald Metcalf for his 
counsel in the preparation of this paper. 
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